Rho kinase, a promising drug target for neurological disorders

Nature Reviews Drug Discovery

Volumn 4, Issue 5, 2005, Pages 387-398

  Mueller, Bernard K ^a   Mack, Helmut ^a   Teusch, Nicole ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (1H PYRROLO[2,3 B]PYRIDIN 4 YL)CYCLOHEXANECARBOXAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DIMETHYLFASUDIL; FASUDIL; GGTI 298; H 1152; IBUPROFEN; INDOMETACIN; ISOPROTEIN; LUTEOLIN; LYSOPHOSPHATIDIC ACID; METHYLPREDNISOLONE; MEVINOLIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PROTEIN SERINE THREONINE KINASE; RHO KINASE; RHO KINASE INHIBITOR; SULINDAC SULFIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN INJURY; BRAIN VASOSPASM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; INFLAMMATORY DISEASE; INHIBITION KINETICS; MAMMAL; MULTIPLE SCLEROSIS; NERVE FIBER GROWTH; NERVE REGENERATION; NERVE SPROUTING; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; STABLE ANGINA PECTORIS; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TREATMENT INDICATION; VERTEBRATE;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVOUS SYSTEM DISEASES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 18944372230     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1719     Document Type: Review

References (133)

1. Van Aelst, L. & D'Souza-Schorey, C. Rho GTPases and signaling networks. Genes Dev. 11, 2295-2322 (1997).
2. Burridge, K. & Wennerberg, K. Rho and Rac take center stage. Cell 116, 167-179 (2004).
3. Bishop, A. & Hall, A. Rho GTPases and their effector proteins. Biochem. J. 348, 241-255 (2000).
4. Rossman, K. L., Der, C. J. & Sondek, J. GEF means go: turning on Rho GTPases with guanine nucleotide-exchange factors. Nature Rev. Mol. Cell Biol. 6, 167-180 (2005).
5. Matsui et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for the small GTP binding protein Rho. EMBO J. 15, 2208-2216 (1996).
6. Ishizaki et al. The small GTP-binding proteinRho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 15, 1885-1893 (1996).
7. Leung, T., Manser, E., Tan, L. & Lim, L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to the peripheral membranes. J. Biol. Chem. 270, 29051-29054 (1996).
8. Nagawa, O. et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 392, 189-193 (1996).
9. Amano, M., Fukata, Y. & Kaibuchi, K. Regulation and function of Rho-associated kinase. Exp. Cell Res. 261, 44-51 (2000).
10. Riento, K. & Ridley, A. ROCKs: multifunctional kinases in cell behaviour. Nature Rev. Mol. Cell. Bio. 4, 446-456 (2003).
11. Hashimoto, R. et al. Distribution of Rho-kinase in the bovine brain. Biochem. Biophys. Res. Commun. 263, 575-579 (1999).
12. Komagome, R., Kimura, K. & Saito, M. Postnatal changes in Rho and Rho-related proteins in the mouse brain. Jpn J. Vet. Res. 47, 127-133 (2000).
13. Amano, M. et al. The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity. J. Biol. Chem. 274, 32418-32424 (1999).
14. Tan, I., Seow, K. T., Lim, L. & Leung, T. Intermolecular and intramolecular interactions regulate the catalytic activity of myotonic dystrophy kinase-related Cdc42-binding kinase. Mol. Cell. Biol. 21, 2767-2778 (2002).
15. Bush, E. W., Helmke, S. M., Birnbaum, R. A. & Perryman, M. B. Myotonic dystrophy protein kinase domains mediate localization, oligomerization, novel catalytic activity and autoinhibition. Biochemistry 39, 8480-8490 (2000).
16. Shimizu, T. Ihara, K., Maesaki, R., Amano, M., Kaibuchi, K. & Hakoshima, T. Parallel coiled-coil association of the RhoA binding domain in Rho-kinase. J. Biol. Chem. 278, 46046-46051 (2003).
17. Dvorsky, R., Blumenstein, L., Vetter, I. & Ahmadian, M. R. Structural insights into the interaction of ROCKI with the switch regions of RhoA. J. Biol. Chem. 279, 7098-7104 (2004).
18. Doran, J., Lui, X., Taslimi, P. Saadat, A. & Fox, T. New insights into the structure-function relationships of Rho-associated kinase: A thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications. Biochem. J. 384, 255-262 (2004).
19. Turner, M. S., Fen Fen, L., Trauger, J. W., Stephens, J. & LoGrasso, P. Characterization and purification of truncated human Rho-kinase II expressed in Sf-21 cells. Arch. Biochem. Biophys. 405, 13-20 (2002).
20. Fu, X., Gong, M. C., Jia, T., Somlyo A. V. & Somlyo, A. P. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTP S-, and phorbol ester-induced Ca-sensitization of smooth muscle. FEBS Lett. 440, 183-187 (1998).
21. 2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circ. Res. 91, 112-119 (2002).
22. Sebbagh, M. et al. Caspase-3-mediated cleavage of ROCKI induces MLC phosphorylation and apoptotic membrane blebbing. Nature Cell Biol. 3, 346-352 (2001).
23. Coleman, M. L. et al. Membrane blebbing during apoptosis results from Caspase-mediated activation of ROCKI. Nature Cell Biol. 3, 339-345 (2001).
24. Leung, T., Chen, X. Q., Manser, E. & Lim, L. The p160 RhoA-binding kinase ROK is a member of a kinase family and is involved in the reorganization of the cyloskeleton. Mol. Cell. Biol. 16, 5313-5327 (1996).
25. Somlyo, A. P. & Somlyo, A. V. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. 522, 177-185 (2000).
26. Kimura, K. et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248 (1996).
27. Sumi, T., Matsumoto, K. & Nakamura, T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J. Biol. Chem. 276, 670-676 (2001).
28. Ohashi, K. et al. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 275, 3577-3582 (2000).
29. Goto, H. et al. Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specificially phosphorylated during cytokinesis. J. Biol. Chem. 273, 11728-11736 (1998).
30. Kosako, H. et al. Phosphorylation of glial filbrillary acidic protein at the same sites by cleavage furrow kinase and Rho-associated kinase. J. Biol. Chem. 272, 10333-10336 (1997).
31. Hashimoto, R. et al. Domain and site-specific phosphorylation of bovine NF-L by Rho-associated kinase. Biochem. Biophys. Res. Commun. 245, 407-411 (1998).
32. Amano, M. et al. Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. J. Neurochem. 87, 780-790 (2003).
33. Arimura, N. et al. Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathway for growth cone collapse. J. Biol. Chem. 275, 23973-23980 (2000).
34. Shimizu, Y. et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J. Cell Biol. 168, 941-963 (2005).
35. Thumkeo, D. et al. Targeted disruption of the mouse Rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol. Cell. Biol. 23, 5043-5055 (2003).
36. Shibuya, M. et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J. Neurosurg. 76, 571-577 (1992).
37. Shimokawa, M. et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 40, 751-761 (2002).
38. Hu, E. & Lee, D. ROCK inhibitors as potential therapeutic agents for cardiovascular diseases, Curr. Opin. Investig. Drugs. 4, 1065-1075 (2003).
39. Wettschureck, N. & Offermanns, S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J. Mol. Med. 80, 629-638 (2002).
40. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. 83, 1325-1358 (2003).
41. Sylvester, J. T. The tone of pulmonary smooth muscle: ROK and Rho music? Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L624-L630 (2004).
42. Aznar, S., Fernandez-Valeron, P., Espina, C. & Lacal, J. C. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 206, 181-191 (2004).
43. Sharpe, C. C. & Hendry, B. M. Signaling: focus on Rho in renal disease. J. Am. Soc. Nephrol. 14, 261-264 (2003).
44. Andersson, K. E. & Hedlund, P. New directions for erectile dysfunction therapies. Int. J. Impot. Res. 14 (Suppl. 1) S82-S92 (2002).
45. Dobkin, B. H. & Havron, L. A. Basic advances and new avenues in therapy of spinal cord injury. Annu. Rev. Med. 55, 255-282 (2004).
46. Harkey, H. L., White, E. A., Tibbs, R. E. Jr & Haines, D. E. A clinician's view of spinal cord injury. Anat. Rec. B New Anat. 271, 41-48 (2003).
47. McDonald, J. W. & Sadowsky, C. Spinal-cord injury. Lancet 359, 417-425 (2002).
48. Dumont, R. J. et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin. Neuropharmacol. 24, 254-264 (2001).
49. Schwab, M. E. Nogo and axon regeneration. Curr. Opin. Neurobiol. 14, 118-124 (2004).
50. Fournier, A. E., GrandPre, T. & Strittmatter, S. M. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 409, 341-346 (2001).
51. Domeniconi, M. et al. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 35, 283-290 (2002).
52. Liu, B. P., Fournier, A., GrandPre, T. & Strittmatter, S. M. Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 297, 1190-1193 (2002).
53. Wang, K. C. et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 417, 941-944 (2002).
54. Venkatesh, K. et al. The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. J. Neurosci. 25, 808-822 (2005).
55. Wang, K. C., Kim, J. A., Sivasankaran, R., Segal, R. & He, Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420, 74-78 (2002).
56. Wong, S. T. et al. A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nature Neurosci. 5, 1302-1308 (2002).
57. Mi, S. et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nature Neurosci. 7, 221-228 (2004).
58. Park, J. B. et al. A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 45, 345-351 (2005).
59. Shao, Z. et al. TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 45, 353-359 (2005).
60. Schweigreiter, R. et al. Versican V2 and the central inhibitory domain of Nogo-A inhibit neurite growth via p75NTR/NgR-independent pathways that converge at RhoA. Mol. Cell. Neurosi. 27, 163-174 (2004).
61. Niederost, B., Oertle, T., Fritsche, J., McKinney, R. A. & Bandtlow, C. E. Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. J. Neurosci. 22, 10368-10376 (2002).
62. Schwab, J. M. et al. Spinal cord injury induces lesional expression pattern of the Repulsive Guidance Molecule (RGM). Eur. J. Neurosci. (in the press).
63. He, Z. & Koprivica, V. The Nogo signaling pathway for regeneration block. Annu. Rev. Neurosci. 27, 341-368 (2004).
64. Kullander, K. et al. Role of EphA4 and EphrinB3 in local neuronal circuits that control walking. Science 299, 1889-1892 (2003).
65. Moreau-Fauvarque, C. et al. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. Neuroscience 23, 9229-9239 (2003).
66. Willson, C. A. et al. Upregulation of EphA receptor expression in the injured adult rat spinal cord. Cell Transplant. 11, 229-239 (2002).
67. Miranda, J. D. et al. Induction of Eph B3 after spinal cord injury. Exp. Neurol. 156, 218-222 (1999).
68. Monnier, P. P., Sierra, A., Schwab, J. M., Henke-Fahle, S. & Mueller, B. K. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell. Neurosci. 22, 319-330 (2003).
69. Borisoff, J. F. et al. Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol Cell Neurosci. 22, 405-416 (2003).
70. Swiercz, J. M., Kuner, R., Behrens, J. & Offermanns, S. Plexin-B1 directly interacts with PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology. Neuron 35, 51-63 (2002).
71. Shamah, S. M. et al. EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell 105, 233-244 (2001).
72. Wahl, S., Barth, H., Ciossek, T., Aktories, K. & Mueller, B. K. Ephrin-A5 induces collapse of growth cones by activating Rho and ROCK. J. Cell Biol. 149, 263-270 (2000).
73. Brabeck, C. et al. Lesional expression of RhoA and RhoB following traumatic brain injury in humans. J. Neurotrauma 21, 697-706 (2004).
74. Aimone, J., Leisure L., Perreau, V. & Tallmair, M. Spatial an temporal gene epression profiling of the contused rat spinal cord. Exp. Neurol. 189, 204-221 (2004).
75. Dubreuil, C. I., Winton, M. J. & McKerracher, L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell Biol. 162, 233-243 (2003).
76. Madura, T. et al. Activation of Rho in the injured axons following spinal cord injury. EMBO Rep. 5, 412-417 (2004).
77. Dergham, P. et al. Rho signaling pathway targeted to promote spinal cord repair. J. Neurosci. 22, 6570-6577 (2002).
78. Hara, M. et al. Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J. Neurosurg. Spine 93, 94-101 (2000).
79. Fournier, A. E., Takizawa, B. T. & Strittmatter, S. M. ROCK inhibition enhances axonal regeneration in the injured CNS. J. Neurosci. 23, 1416-1423 (2003).
80. Sung, J. K. et al. A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat Brain Res. 959, 29-38 (2003).
81. Tanaka, H. et al. Cytoplasmic p21 (Cip1/WAF1) enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 127, 155-164 (2004).
82. Citron, M. Strategies for disease modification in Alzheimer's disease. Nature Rev. Neurosci. 5, 677-685 (2004).
83. Selkoe, D. J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nature Cell Biol. 6, 1054-1061 (2004).
84. McGeer, P. L., Schulzer, M. & McGeer, E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432 (1996).
85. 2 receptor antagonists: the Cache County study. Neurology 54, 2066-2071 (2000).
86. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
87. Eriksen, J. L. et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. 112, 440-449 (2003).
88. Zhou, Y. et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho. Science 302, 1215-1217 (2003).
89. Pedrini, S. et al. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med. 2, 69-78 (2005).
90. Neuhaus, O., Stuve, O., Zamvil, S. S. & Hartung, H. P. Are statins a treatment option for multiple sclerosis? Lancet Neurol. 3, 369-371 (2004).
91. Hendriks, J. J. et al. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J. Exp. Med. 200, 1667-1672 (2004).
92. Greenwood, J. et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17, 905-907 (2003).
93. Walters, C. E. et al. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J. Immunol. 168, 4087-4094 (2002).
94. Honing, H. et al. RhoA activation promotes transendothelial migration of monocytes via ROCK. J. Leukoc. Biol. 75, 523-528 (2004).
95. Kakulas, B. A. A review of the neuropathology of human spinal cord injury with emphasis on special features. J. Spinal Cord Med. 22, 119-124 (1999).
96. Kohama, I. et al. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J. Neurosci. 21, 944-950 (2001).
97. Melendez-Vasquez, C. V., Einheber, S. & Salzer, J. L. ROCK regulates schwann cell myelination and formation of associated axonal domains. J. Neurosci. 24, 3953-3963 (2004).
98. Minagar, A., Toledo, E. G., Alexander, J. S. & Kelley, R. E. Pathogenesis of brain and spinal cord atrophy in multiple sclerosis. J. Neuroimaging 14, 5s-10s (2004).
99. Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
100. Toshima Y, Satoh S, Ikegaki I, Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 31, 2245-2250 (2000).
101. Satoh, S. et al. Pharmacological profile of hydroxy fasudil as a selective ROCK inhibitor on ischemic brain damage. Life Sci. 69, 1441-1453 (2001).
102. Kitaoka, Y. et al. Involvement of RhoA and possible neuroprotective effect of fasudil, a ROCK inhibitor, in NMDA-induced neurotoxicity in the rat retina. Brain Res. 1018, 111-118 (2004).
103. Lee, J. K., Kim, J. E., Sivula, M. & Strittmatter, S. M. Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J. Neurosci. 24, 6209-6217 (2004).
104. Wiessner, C. et al. Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. J. Cereb. Blood Flow Metab. 23, 154-165 (2003).
105. Schwab, J. M. et al. CNS injury-induced RGM (Repulsive Guidance Molecule) expression in the adult human brain. Arch. Neurol. (in the press).
106. Ji, R. R. & Strichartz, G. Cell signaling and the genesis of neuropathic pain. Science STKE 252, re 14, 1-19 (2004).
107. Inoue, M. et al. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nature Med. 10, 712-718 (2004).
108. Ramer, L. M., Borisoff, J. F. & Ramer, M. S. Rho-kinase inhibition enhances axonal plasticity and attenuates cold hyperalgesia after dorsal rhizotomy. J Neurosci. 24, 10796-10805 (2004).
109. Tatsumi, S. et al. Involvement of Rho-kinase in inflammatory and neuropathic pain through phosphorylation of myristoylated alanine-rich C-kinase substrate (MARCKS). Neuroscience 131, 491-498 (2005).
110. Uehata, M. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994 (1997).
111. Uehata M., Ono, T., Satoh, H., Yamagami, K. & Kawahara, T. Medicines comprising ROCK inhibitor. European Patent EP0956865A1 (1998).
112. Shimokawa, H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol. 39, 319-327 (2002).
113. Hidaka, H., Matsuura, A. & Matsuzaki, T. Isoquinoline derivatives and drugs. European Patent EP0885888(A1) (1997).
114. Iwakubo, M. & Okada, Y. Isoquinoline derivatives having kinase inhibitory activity and drugs containing the same. World Patent WO 2004024717A1 (2004).
115. Takanashi, S., Naito, Y., Tanaka, H., Uehata, M. & Katayama, K. Amide compounds and use thereof. European Patent EP1270570A1 (2001).
116. Uehata M., Takanashi, S. & Hamaguchi, S. ROCK inhibitor comprising amide compound. Japanese Patent JP2003073357 A2 (2003).
117. Gingras, K. et al. Bioaxone. Synthesis and evaluation of 4-(1-aminoalkyl)-N-(4-pyridyl)-cyclohexanecarboxamides as ROCK inhibitors and neurite outgrowth promoters. Bioorg. Med. Chem. Lett. 14, 4931-4934 (2004).
118. McKerracher, L., Thouin, E. & Lubell, W. D. 1,4-substituted cyclohexane derivatives. World Patent WO 2004022541A1 (2004).
119. Takami, A., Iijima, H., Iwakubo, M. & Okada, Y. Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same. European Patent EP1256574A1 (2001).
120. Nagarathnam, D. Wang, C. H. ROCK inhibitors. World Patent WO2002076977A2 (2002).
121. Feurer, A. et al. Heteroaryloxy-substituted phenylaminopyrimidines as ROCK inhibitors. World Patent WO2004039796A1 (2004).
122. Ishizaki, T. et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Molecular Pharmacology 57, 976-983 (2000).
123. Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105 (2000).
124. Sazaki, Y., Suzuki, M. & Hidaka, H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93, 225-232 (2002).
125. Ikenoya, M. et al. Inhibition of Rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J. Neurochem. 81, 9-16 (2002).
126. Breitenlechner, C. et. al. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 11, 1595-1607 (2003).
127. Hirooka, Y. & Shimokawa, H. Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases. Am. J. Cardiovasc. Drugs 5, 31-39 (2005).
128. Lu, M. et al. Assessment of absortion of ROCK inhibitor at different sites of the human gastrointestinal tract. Am. Soc. Clin. Pharmacol. Ther. P6, PI-13 (2004).
129. Takanashi, Y. et al. Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 48, 894-900 (2001).
130. Ishida, T., Takanashi, Y., Doi, H., Yamamoto, I. & Kiwada, H. Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes. Int. J. Pharm. 232, 59-67 (2002).
131. Nagatoya, K. et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 61, 1684-1695 (2002).
132. Narumiya, S., Ishizaki, T. & Uehata, M. Use and properties of ROCK-specific inhibitor Y-27632. Meth Enzymol. 325, 273-284 (2000).
133. Wei, L. et al. Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development 128, 2953-2962 (2001).